Royalty

BioArctic’s Q2 2025 royalties surged to SEK 162.5 million due to strong Leqembi (lecanemab) sales, developed with Eisai, reaching JPY 23.1 billion. This included a one-time China stockpiling effect of JPY 5.3 billion. Excluding this, sales were JPY 17.8 billion, with royalties of approximately SEK 125 million. BioArctic will release its full Q2 report on August 28, focusing on Leqembi’s sustainable growth. Leqembi, targeting early Alzheimer’s, is approved in 46 countries and under review in 10 more.

BP Prudhoe Bay Royalty Trust will not distribute a dividend for the quarter ending June 30, 2025. This is due to negative Per Barrel Royalty calculations, driven by low WTI prices and high costs. The Trust ceased operations on December 31, 2024, and its units will be delisted from the NYSE and commence trading on OTC Pink on July 1, 2025, facing reduced liquidity. All operations are now in the process of winding down.